<?xml version="1.0" encoding="UTF-8"?>
<clinical_study rank="82100">
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on April 10, 2017</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT02036541</url>
  </required_header>
  <id_info>
    <org_study_id>P13-001</org_study_id>
    <nct_id>NCT02036541</nct_id>
  </id_info>
  <brief_title>AqueSys XEN 45 Glaucoma Implant in Refractory Glaucoma</brief_title>
  <official_title>A Prospective, Multicenter Clinical Trial Designed to Evaluate the Safety and Performance of the AqueSys XEN 45 Glaucoma Implant in Subjects With Refractory Glaucoma</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>AqueSys, Inc.</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>Allergan</agency>
      <agency_class>Industry</agency_class>
    </collaborator>
  </sponsors>
  <source>AqueSys, Inc.</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      To establish the safety and performance of the AqueSys XEN 45 Glaucoma Implant in eyes with
      refractory glaucoma.
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      A prospective, multi-center, single arm, open-label clinical trial to evaluate the safety
      and IOP lowering performance of the AqueSys XEN 45 Glaucoma Implant in refractory glaucoma
      patients.
    </textblock>
  </detailed_description>
  <overall_status>Active, not recruiting</overall_status>
  <start_date>January 2013</start_date>
  <completion_date type="Anticipated">September 2016</completion_date>
  <primary_completion_date type="Actual">February 2016</primary_completion_date>
  <phase>Phase 3</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <intervention_model>Single Group Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>Open Label</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Proportion of subjects achieving a 20% or greater reduction in IOP from baseline on the same or less number of medications</measure>
    <time_frame>12 Months</time_frame>
  </primary_outcome>
  <secondary_outcome>
    <measure>Mean change in IOP from baseline</measure>
    <time_frame>12 Months</time_frame>
  </secondary_outcome>
  <number_of_arms>1</number_of_arms>
  <enrollment type="Anticipated">60</enrollment>
  <condition>Glaucoma</condition>
  <condition>Glaucoma, Open Angle</condition>
  <arm_group>
    <arm_group_label>AqueSys XEN 45 Glaucoma Implant</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
  </arm_group>
  <intervention>
    <intervention_type>Device</intervention_type>
    <intervention_name>AqueSys XEN 45 Glaucoma Implant</intervention_name>
    <description>Placement of the AqueSys XEN 45 Glaucoma Implant in the study eye</description>
    <arm_group_label>AqueSys XEN 45 Glaucoma Implant</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Diagnosis of Refractory Glaucoma

          -  Maximally-tolerated medicated IOP at two preoperative visits of ≥20 mmHg and ≤35 mmHg

          -  Visual field mean deviation score of -3 dB or worse

          -  Shaffer Angle Grade ≥ 3

          -  Area of free, healthy and mobile conjunctiva in the targeted quadrant

        Exclusion Criteria:

          -  Active Neovascular Glaucoma

          -  Previous glaucoma shunt/valve in the targeted quadrant

          -  History of corneal surgery, opacities or disease/pathology

          -  Anticipated need for ocular surgery

          -  Non-study eye with BCVA of 20/200 or worse
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>45 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Richard A Lewis, M.D.</last_name>
    <role>Study Chair</role>
    <affiliation>Grutzmacher, Lewis &amp; Sierra Surgical Eye Specialists</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>George R. Reiss, MD PC</name>
      <address>
        <city>Glendale</city>
        <state>Arizona</state>
        <zip>85306</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Vold Vision</name>
      <address>
        <city>Fayetteville</city>
        <state>Arkansas</state>
        <zip>72704</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Montebello Eye Center</name>
      <address>
        <city>Montebello</city>
        <state>California</state>
        <zip>90640</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>San Diego Eye Care Center</name>
      <address>
        <city>Oceanside</city>
        <state>California</state>
        <zip>92056</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Palo Alto Eye Group</name>
      <address>
        <city>Palo Alto</city>
        <state>California</state>
        <zip>94306</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Eye Center of Northern Colorado</name>
      <address>
        <city>Fort Collins</city>
        <state>Colorado</state>
        <zip>80525</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Stiles Eyecare Excellence &amp; Glaucoma Institute</name>
      <address>
        <city>Overland Park</city>
        <state>Kansas</state>
        <zip>66213</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Washington University in St. Louis, Department of Ophthalmology</name>
      <address>
        <city>St. Louis</city>
        <state>Missouri</state>
        <zip>63110</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>New York Eye and Ear Infirmary</name>
      <address>
        <city>New York</city>
        <state>New York</state>
        <zip>10003</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Glaucoma Associates of Texas</name>
      <address>
        <city>Dallas</city>
        <state>Texas</state>
        <zip>75231</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>R and R Eye Research, LLC</name>
      <address>
        <city>San Antonio</city>
        <state>Texas</state>
        <zip>78229</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Spokane Eye Clinic</name>
      <address>
        <city>Spokane</city>
        <state>Washington</state>
        <zip>99204</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <verification_date>July 2016</verification_date>
  <lastchanged_date>July 11, 2016</lastchanged_date>
  <firstreceived_date>January 13, 2014</firstreceived_date>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>Glaucoma Implant</keyword>
  <keyword>Trabeculectomy</keyword>
  <keyword>POAG</keyword>
  <keyword>Primary Open Angle Glaucoma</keyword>
  <keyword>Pseudoexfoliation Glaucoma</keyword>
  <keyword>Pigmentary Glaucoma</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm  -->
    <mesh_term>Glaucoma</mesh_term>
    <mesh_term>Glaucoma, Open-Angle</mesh_term>
  </condition_browse>
  <!-- Results have not yet been posted for this study                                -->
</clinical_study>
